Pharmaceutical Manufacturing Research Association Transfers Health Policy Responsibilities to a New Bull
Simon Bull, previously the Chief Executive of CMTUK, a charity organisation based in Bournemouth, England, focused on supporting those affected by Charcot-Marie-Tooth disease and related conditions, has embarked on a new journey within the global pharmaceutical industry.
Bull's new role sees him working as a Health Policy Manager at the Association of Research-Based Pharmaceutical Companies (ARPC), a key player in the industry. The ARPC, headquartered in Brussels, Belgium, represents over 40 member companies and plays a significant role in shaping health policy at the European level.
In his new position, Bull will report directly to Sven Prietzel, a prominent figure within the ARPC. His responsibilities will include developing and implementing health policies, advocating for evidence-based policies, and collaborating with stakeholders in the pharmaceutical industry.
Prior to joining the ARPC, Bull spent two years as a Public Policy and Political Communications Advisor at the German Tourism Industry Association. Before that, he served as a Health Policy Manager at the Association of Research-Based Pharmaceutical Companies, a role he took up on May 1st, 2023.
Bull's work experience extends beyond the healthcare sector. He previously held a role as a Health Policy Manager at the Association of Research-Based Pharmaceutical Companies, a position he assumed on May 1st, 2023, before moving to the German Tourism Industry Association.
In his previous roles, Bull demonstrated a keen understanding of policy development and advocacy, skills that are expected to serve him well in his new position at the ARPC. The ARPC is committed to improving health and well-being through the research, development, and manufacture of innovative pharmaceutical products.
While the Chair of the Trustee Board at CMTUK is typically the individual who the Chief Executive reports to, the reporting structure within the ARPC is not explicitly provided. However, in most charity governance structures, the Chief Executive reports to the Chair of the Trustee Board. In this case, Anton James holds that position.
Bull's tenure at CMTUK marked a successful period for the organisation, and his contributions are still felt in the support provided to those affected by Charcot-Marie-Tooth disease and related conditions. His move to the ARPC signifies a shift in focus, but his commitment to improving health and well-being remains unwavering.
In his new role as Health Policy Manager at the Association of Research-Based Pharmaceutical Companies (ARPC), Simon Bull will continue to apply his skills in policy development and advocacy, now focusing on improving health and wellness through science-based medical-condition research and evidence-based policy communication within the global pharmaceutical industry. Despite his move from CMTUK, Bull's dedication to supporting those affected by Charcot-Marie-Tooth disease and related conditions endures.
